4 completed, 3 active not recruiting, 3 recruiting. 4 Phase 1, 4 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
| Phase 2 | 4 | Completed 2, Active not recruiting 1, Recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Stage 0is Bladder Cancer AJCC v8: new trials by email Literature Review of Stage 0is Bladder Cancer AJCC v8 trials Research Report on Stage 0is Bladder Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial Internet-Based Intervention, Best Practice, Exercise Intervention - Localized Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Not applicable | Recruiting | University of Washington | 100 | 2026-03-11 | 2026-07-06 |
| In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial BCG Solution, Cystoscopy, Docetaxel - Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 1 / Phase 2 | Recruiting | Mayo Clinic | 40 | 2025-04-21 | 2026-10-08 |
| PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer PLZ4-coated paclitaxel loaded micelles (PPM) - Recurrent Non-Muscle Invasive Bladder Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 1 | Recruiting | University of California, Davis | 12 | 2023-11-22 | 2026-03-13 |
| IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer PD-L1/IDO Peptide Vaccine, Pembrolizumab - High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8 | Phase 1 | Active not recruiting | University of California, Davis | 6 | 2023-04-19 | 2026-07-16 |
| Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship Behavioral Dietary Intervention, Educational Intervention, Questionnaire Administration - Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8 | Phase 1 | Completed | Roswell Park Cancer Institute | 49 | 2021-04-05 | 2024-08-28 |
| Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer Acupuncture Therapy, BCG Solution, Best Practice - Bladder Urothelial Carcinoma In Situ, Recurrent Bladder Urothelial Carcinoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 45 | 2021-01-22 | 2024-01-02 |
| Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes Patient Monitoring, Questionnaire Administration - Clinical Stage 0 Esophageal Adenocarcinoma AJCC v8, Clinical Stage 0 Esophageal Squamous Cell Carcinoma AJCC v8 | Completed | City of Hope Medical Center | 22 | 2020-08-11 | 2026-10-14 | |
| Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Bladder Flat Urothelial Carcinoma In Situ, Non-Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 161 | 2020-03-18 | 2026-11-18 |
| Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study Non-Interventional Study - Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8 | Active not recruiting | Mayo Clinic | 204 | 2018-10-12 | 2026-04-17 | |
| Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer Erlotinib Hydrochloride - Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 34 | 2008-06-10 | 2020-09-10 |
Urinary Bladder Neoplasms (10) · Non-Muscle Invasive Bladder Neoplasms (2) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Gastrointestinal Neoplasms (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Prostatic Neoplasms (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1) · Urogenital Neoplasms (1) · Uterine Cervical Neoplasms (1)
Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Male Urogenital Diseases (10) · Neoplasms by Site (10) · Urinary Bladder Diseases (10) · Urogenital Diseases (10) · Urologic Diseases (10) · Urologic Neoplasms (10) · Neoplasms (9) · Urogenital Neoplasms (9) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Adenocarcinoma (1) · Adnexal Diseases (1)
Cystoscopy (2) · Early Intervention, Educational (2) · Gemcitabine (2) · Practice Guidelines as Topic (2) · Standard of Care (2) · pembrolizumab (2) · Acupuncture Therapy (1) · Biopsy (1) · Docetaxel (1) · Educational Status (1) · Erlotinib Hydrochloride (1) · Home Care Services (1) · House Calls (1) · Interviews as Topic (1) · Magnetic Resonance Spectroscopy (1)
Mayo Clinic (2) · University of California, Davis (2) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Roswell Park Cancer Institute (1) · University of Washington (1)
United States (10) · Guam (1) · Puerto Rico (1)
Mamta Parikh (2) · Arlene Siefker-Radtke (1) · Karen Yeary (1) · Laleh Melstrom (1) · Mark D. Tyson, M.D., M.P.H. (1) · Michael E Woods (1) · Sarah P. Psutka (1) · Sarah Psutka, MD, MSc (1) · Timothy D. Lyon, MD (1)
P30CA093373 (2), P30CA015704 (1), P30CA016672 (1), P30CA033572 (1), R21CA253910 (1), U10CA180821 (1), UL1TR002377 (1)